0.97
Precedente Chiudi:
$0.972
Aprire:
$0.98
Volume 24 ore:
15,752
Relative Volume:
0.12
Capitalizzazione di mercato:
$34.72M
Reddito:
-
Utile/perdita netta:
$-9.16M
Rapporto P/E:
-1.7018
EPS:
-0.57
Flusso di cassa netto:
$-8.75M
1 W Prestazione:
+2.11%
1M Prestazione:
-3.00%
6M Prestazione:
-6.22%
1 anno Prestazione:
-19.83%
Renovorx Inc Stock (RNXT) Company Profile
Nome
Renovorx Inc
Settore
Industria
Telefono
408-800-2649
Indirizzo
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Confronta RNXT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RNXT
Renovorx Inc
|
0.97 | 34.72M | 0 | -9.16M | -8.75M | -0.57 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.91 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
565.40 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
628.63 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
258.76 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
248.44 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovorx Inc Borsa (RNXT) Ultime notizie
Johns Hopkins Medicine Initiates Patient Enrollment For Renovorx'S Ongoing Phase III Tiger-Pac Clinical Trial - marketscreener.com
Johns Hopkins Medicine Accelerates RenovoRx's Breakthrough Pancreatic Cancer Trial Progress - Stock Titan
RenovoRx (NASDAQ:RNXT) Price Target Raised to $11.00 at Ascendiant Capital Markets - Defense World
RenovoRx Reports Initial Revenue and Clinical Trial Progress - MSN
RenovoRx CMO Makes Bold Stock Purchase! - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock - Investing.com Australia
RenovoRx chief medical officer Agah Ramtin buys $13,500 in stock By Investing.com - Investing.com Canada
RenovoRx chief medical officer Agah Ramtin buys $13,500 in common stock By Investing.com - Investing.com South Africa
RenovoRx ramps up production of FDA-cleared RenovoCath By Investing.com - Investing.com India
New Jersey Patients Receiving First-of-Its-Kind Catheter Based Pancreatic Cancer Treatment | Newswise - Newswise
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock - Investing.com Australia
RenovoRx CEO Shaun Bagai acquires $6,821 in common stock By Investing.com - Investing.com Canada
RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community - BioSpace
RenovoRx ramps up production of FDA-cleared RenovoCath - Investing.com
Renovorx Increases U.S. Production Of Renovocath Devices To Meet Growing Demand From Oncology Community - marketscreener.com
Medical Device Maker RenovoRx Eyes $400M Market With Surging RenovoCath Demand - Stock Titan
RenovoRx CMO Makes Bold Stock Purchase - TipRanks
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock By Investing.com - Investing.com India
RenovoRx chief medical officer Agah Ramtin buys $16,000 in stock - Investing.com
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock By Investing.com - Investing.com India
Top Executives Make Bold Moves with RenovoRx Stock Purchases! - TipRanks
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com - Investing.com Canada
RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock - Investing.com Australia
RenovoRx Executives Increase Their Holdings - TradingView
RenovoRx CMO Agah Ramtin purchases $24,399 in common stock - Investing.com
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai acquires $8,300 in common stock - Investing.com
Renovorx director Marton Laurence buys $10,218 in common stock By Investing.com - Investing.com UK
RenovoRx CMO Makes a Bold Move with Major Stock Purchase - TipRanks
RenovoRx Executives Increase Stake in Company - TradingView
Renovorx director Marton Laurence buys $10,218 in common stock - Investing.com
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares - Investing.com Australia
Renovorx chief medical officer Agah Ramtin buys $21,840 in shares By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock By Investing.com - Investing.com Canada
RenovoRx CEO Shaun Bagai purchases $8,300 in company stock - Investing.com
RenovoRx stock hits 52-week low at $0.77 amid market challenges - Investing.com Australia
RenovoRx stock hits 52-week low at $0.77 amid market challenges By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms “Buy” Rating for RenovoRx (NASDAQ:RNXT) - Defense World
H.C. Wainwright maintains Buy rating on RenovoRx stock By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy rating on RenovoRx stock - Investing.com Australia
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th - Business Wire
Renovorx Inc Azioni (RNXT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Renovorx Inc Azioni (RNXT) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Bagai Shaun | Chief Executive Officer |
Apr 15 '25 |
Buy |
0.91 |
7,500 |
6,821 |
320,040 |
Agah Ramtin | Chief Medical Officer |
Apr 11 '25 |
Buy |
0.80 |
20,000 |
16,000 |
1,098,460 |
Kocak Ron | VP Controller and PAO |
Apr 10 '25 |
Buy |
0.79 |
6,500 |
5,135 |
12,595 |
Kocak Ron | VP Controller and PAO |
Apr 09 '25 |
Buy |
0.80 |
6,000 |
4,800 |
6,095 |
Kocak Ron | VP Controller and PAO |
Apr 08 '25 |
Buy |
0.80 |
95 |
76 |
95 |
Agah Ramtin | Chief Medical Officer |
Apr 09 '25 |
Buy |
0.81 |
30,000 |
24,399 |
1,078,460 |
Bagai Shaun | Chief Executive Officer |
Apr 09 '25 |
Buy |
0.83 |
10,000 |
8,300 |
312,540 |
Marton Laurence | Director |
Apr 08 '25 |
Buy |
0.85 |
12,050 |
10,218 |
45,684 |
Agah Ramtin | Chief Medical Officer |
Apr 08 '25 |
Buy |
0.84 |
26,000 |
21,840 |
1,048,460 |
Bagai Shaun | Chief Executive Officer |
Apr 07 '25 |
Buy |
0.83 |
10,000 |
8,300 |
302,540 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):